Slow response to entecavir treatment in treatment-naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants

Antiviral Therapy

Volumn 19, Issue 2, 2014, Pages 201-209

  Solmone, Mariacarmela ^a   Giombini, Emanuela ^a   Vincenti, Donatella ^a   Rozera, Gabriella ^a   Testa, Angela ^a   Moscetti, Alessandra ^b   Catalano, Manuela ^b   Abbate, Isabella ^a   Capobianchi, Maria R ^a   Menzo, Stefano ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; EPITOPE; HEPATITIS B SURFACE ANTIGEN; RNA DIRECTED DNA POLYMERASE; ANTIVIRUS AGENT; GUANINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SENSITIVITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MIDDLE AGED; MUTATIONAL ANALYSIS; OPEN READING FRAME; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PYROSEQUENCING; TREATMENT RESPONSE; ULTRA DEEP PYROSEQUENCING; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD; ANALOGS AND DERIVATIVES; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS B, CHRONIC; PHYLOGENY; VIROLOGY;

ANTIVIRAL AGENTS; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MIDDLE AGED; PHYLOGENY; VIRAL LOAD;

EID: 84898603490     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2700     Document Type: Article

References (22)

1. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigenpositive chronic hepatitis B. Hepatology 2010; 51:422-430.
2. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011; 26 Suppl 1:138-143.
3. Ono A, Suzuki F, Kawamura Y, et al. Long-Term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol 2012; 57:508-514.
4. Tenney DJ. Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antivir Ther 2010; 15:529-535.
5. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51:902-911.
6. Tenney DJ, Rose RE, Baldick CJ, et al. Long-Term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1514.
7. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012; 19:377-386.
8. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drugnaive patients and to detect minor variants in reverse transcriptase and hepatitis B s antigen. J Virol 2009; 83:1718-1726.
9. Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-Transcriptase inhibitor (NRTI)-Treated patients and NRTI-naive patients. J Infect Dis 2009; 199:1275-1285.
10. Fang J, Wichroski MJ, Levine SM, et al. Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. Antimicrob Agents Chemother 2009; 53:2762-2772.
11. Nishijima N, Marusawa H, Ueda Y, et al. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS ONE 2012; 4:e35052.
12. Rodriguez-Frías F, Tabernero D, Quer J, et al. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS ONE 2012; 7:e37874.
13. Köck J, Blum HE. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol 2008; 89:1184-1191.
14. Reuman EC, Margeridon-Thermet S, Caudill HB, et al. A classification model for G-To-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads. Bioinformatics 2010; 26:2929-2932.
15. Liu F, Chen L, Yu DM, et al. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut 2011; 60:1269-1277.
16. Nayersina R, Fowler P, Guilhot S, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993; 150:4659-4671.
17. Loirat D, Lemonnier FA, Michel ML. Multiepitopic HLA-A. 0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 2000; 165:4748-4755.
18. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:4398-4402.
19. Wolters LM, Hansen BE, Niesters HG, et al. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol 2002; 37:253-258.
20. Colombatto P, Civitano L, Bizzarri R, et al. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-A2a, lamivudine and combination therapy. Antivir Ther 2006; 11:197-212.
21. Cheng Y, Guindon S, Rodrigo A, Lim SG. Increased viral quasispecies evolutionin HBeAg seroconverter patients treated with oral nucleoside therapy. J Hepatol 2013; 58:217-224.
22. Suzuki F, Tsubota A, Arase Y, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003; 46:182-189.